Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:36:59.623Z.
Calculation as of: 2026-10-06T13:36:59.623Z.
Quote observation: 2026-10-06T13:33:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 28ff4bc206842fc4bf4b39bc6a519bf9e708a216f8b2554427075e3ddc5a9144
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
CytoMed Therapeutics Limited
Market Cap
$10.86M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.21M
Price/OCF Ratio
N/A
TTM Avg
6.96
3Y Avg
6.96
5Y Avg
6.96
Market Cap
$11.50M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.68M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $10.86M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.27M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | N/A | 6.96 | 6.96 | 6.96 |
| Cerenome, Inc. (CNSY)vs › | $11.29M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $11.09M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.50M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.73M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $10.68M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.70M | N/A | 9.81 | 9.81 | 9.81 |
| Cytosorbents Corporation (CTSO)vs › | $12.07M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
